Literature DB >> 24246975

The human gut microbiome and its dysfunctions.

Stanislas Mondot1, Tomas de Wouters, Joël Doré, Patricia Lepage.   

Abstract

The human gastrointestinal tract hosts more than 100 trillion bacteria and archaea, which together make up the gut microbiota. The amount of bacteria in the human gut outnumbers human cells by a factor of 10, but some finely tuned mechanisms allow these microorganisms to colonize and survive within the host in a mutual relationship. The human gut microbiota co-evolved with humans to achieve a symbiotic relationship leading to physiological homeostasis. The microbiota provides crucial functions that human cannot exert themselves while the human host provides a nutrient-rich environment. Chaotic in the early stages of life, the assembly of the human gut microbiota remains globally stable over time in healthy conditions and absence of perturbation. Following perturbation, such as antibiotic treatment, bacteria will recolonize the niches with a composition and diversity similar to the basal level since the ecosystem is highly resilient. Yet, recurrent perturbations lead to a decrease in resilience capacity of the gut microbiome. Shifts in the bacterial composition and diversity of the human gut microbiota have been associated with intestinal dysfunctions such as inflammatory bowel disease and obesity. More than specific bacteria, a general destructuration of the ecosystem seems to be involved in these pathologies. Application of metagenomics to this environment may help in deciphering key functions and correlation networks specifically involved in health maintenance. In term, fecal transplant and synthetic microbiome transplant might be promising therapies for dysbiosis-associated diseases.

Entities:  

Mesh:

Year:  2013        PMID: 24246975     DOI: 10.1159/000354678

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  31 in total

Review 1.  Connection between gut microbiome and the development of obesity.

Authors:  Cuiting Zhi; Jingqing Huang; Jin Wang; Hua Cao; Yan Bai; Jiao Guo; Zhengquan Su
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-07-31       Impact factor: 3.267

2.  To flush or not to flush … that is a question.

Authors:  Bernard Perbal
Journal:  J Cell Commun Signal       Date:  2016-11-07       Impact factor: 5.782

Review 3.  The intestinal microbiota: its role in health and disease.

Authors:  Luc Biedermann; Gerhard Rogler
Journal:  Eur J Pediatr       Date:  2015-01-07       Impact factor: 3.183

Review 4.  Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate.

Authors:  Antonella Gallo; Giovanna Passaro; Antonio Gasbarrini; Raffaele Landolfi; Massimo Montalto
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

Review 5.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

Review 6.  Effect of commensals and probiotics on visceral sensitivity and pain in irritable bowel syndrome.

Authors:  Vassilia Theodorou; Afifa Ait Belgnaoui; Simona Agostini; Helene Eutamene
Journal:  Gut Microbes       Date:  2014 May-Jun

Review 7.  Gut microbiota and GLP-1.

Authors:  Amandine Everard; Patrice D Cani
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

Review 8.  Immune-directed support of rich microbial communities in the gut has ancient roots.

Authors:  Larry J Dishaw; John P Cannon; Gary W Litman; William Parker
Journal:  Dev Comp Immunol       Date:  2014-06-28       Impact factor: 3.636

9.  Using bugs as drugs: Microbial ecosystem therapeutics.

Authors:  E Allen-Vercoe; E O Petrof
Journal:  Can Commun Dis Rep       Date:  2015-11-19

Review 10.  Gut microbiota and obesity.

Authors:  Philippe Gérard
Journal:  Cell Mol Life Sci       Date:  2015-10-12       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.